1. Please click here [1] to download the group picture of your seminar.
2. Presentations:
1. Therapeutic drug monitoring for all drugs and for all patients? [2]
Dr Ute Blassmann [3], Heidelberg University Hospital, Germany
2. Do we need therapeutic drug monitoring for beta lactams or can we just use prolonged infusions? [4]
Dr Ute Blassmann [3], Heidelberg University Hospital, Germany
3. The impact of PK/PD for clinical decisions [5]
Dr Anouk Muller [6], HaaglandenMC, The Hague and ErasmusMC, Rotterdam
4. MIC directed therapy: why, when and what are the pitfalls? [7]
Dr Anouk Muller [6], HaaglandenMC, The Hague and ErasmusMC, Rotterdam
5. Interactive Part – clinical cases – PK/PD [8]
Prof Dr Isabel Spriet [9], UZ Leuven, Belgium
Dr Peter Declercq [10], University Hospitals Leuven, Belgium
6. Implementation of check of medication appropriateness: what can the computer do for ABS? [11]
Prof Dr Isabel Spriet [9], UZ Leuven, Belgium
7. Antifungal therapy: what comes out of the pipeline in the near future? [12]
Prof William Hope* [13], University of Liverpool, United Kingdom
8. TDM and PK/PD in antifungal therapy: when and why? [14]
Prof William Hope* [13], University of Liverpool, United Kingdom
9. Antimicrobial prophylaxis in HSCT-patients: guidelines and evidence [15]
Dr Philipp Wohlfarth [16], Medical University of Vienna, Austria
10. Hygiene measures, isolation and therapy [17]
Prof Dr Annette Schuermans [18], University Hospitals Leuven, Belgium
11. What’s really new in antibiotic therapy [19]
Prof Dr Martin J. Hug [20], Institute of Pharmaceutical Sciences, University of Freiburg, Germany
12. Interactive Part - PKPD & TDM of antifungals [21]
Prof Dr Isabel Spriet [9], UZ Leuven, Belgium
Prof William Hope* [13], University of Liverpool, United Kingdom
Links
[1] https://www.eahp.eu/sites/default/files/s1_2.png
[2] https://www.eahp.eu/sites/default/files/1._therapeutic_drug_monitoring_for_all_drugs_and_for_all_patients.pdf
[3] http://www.eahp.eu/content/dr-ute-blassmann
[4] https://www.eahp.eu/sites/default/files/2._do_we_need_therapeutic_drug_monitoring_for_beta_lactams_or_can_we_just_use_prolonged_infusions.pdf
[5] https://www.eahp.eu/sites/default/files/3._the_impact_of_pkpd_for_clinical_decisions_0.pdf
[6] https://www.eahp.eu/content/dr-anouk-muller
[7] https://www.eahp.eu/sites/default/files/4._mic_directed_therapy_why_when_and_what_are_the_pitfalls.pdf
[8] https://www.eahp.eu/sites/default/files/5._interactive_part_-_clinical_cases_-_pkpd.pdf
[9] http://www.eahp.eu/content/prof-dr-isabel-spriet
[10] http://www.eahp.eu/content/dr-peter-declercq
[11] https://www.eahp.eu/sites/default/files/6._implementation_of_check_of_medication_appropriateness_what_can_the_computer_do_for_abs.pdf
[12] https://www.eahp.eu/sites/default/files/7._antifungal_therapy_what_comes_out_of_the_pipeline_in_the_near_future.pdf
[13] http://www.eahp.eu/content/prof-william-hope
[14] https://www.eahp.eu/sites/default/files/8._tdm_and_pkpd_in_antifungal_therapy_when_and_why.pdf
[15] https://www.eahp.eu/sites/default/files/9._antimicrobial_prophylaxis_in_hsctpatients_guidelines_and_evidence.pdf
[16] http://www.eahp.eu/content/dr-philipp-wohlfarth
[17] https://www.eahp.eu/sites/default/files/10._hygiene_measures_isolation_and_therapy.pdf
[18] http://www.eahp.eu/content/prof-dr-annette-schuermans
[19] https://www.eahp.eu/sites/default/files/11._whats_reallly_new_in_antibiotic_therapy_mjh.pdf
[20] http://www.eahp.eu/content/prof-dr-martin-j-hug-0
[21] https://www.eahp.eu/sites/default/files/12._interactive_part_-_pkpd_tdm_of_antifungals.pdf